ASCO GI 2025: Everolimus and Lanreotide Combo as a Breakthrough for Gastroenteropancreatic Neuroendocrine Tumors
The combination of everolimus, an mTOR inhibitor, and lanreotide, a hormone-blocking agent, has shown significant promise in extending progression-free survival (PFS) and improving objective response rates (ORR) for patients with grade 1 or 2 gastroenteropancreatic neuroendocrine tumors (GEP-NETs). This first-line treatment strategy was particularly beneficial for patients with high-risk prognostic factors, showing better outcomes compared to everolimus alone.